Connor, Clark & Lunn Investment Management (CC&L)
CLDX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Celldex Therapeutics CLDX Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-8,158
Closed -$342K 1418
2024
Q1
$342K Sell
8,158
-20,380
-71% -$855K ﹤0.01% 1223
2023
Q4
$1.13M Buy
28,538
+10,383
+57% +$412K 0.01% 828
2023
Q3
$500K Buy
+18,155
New +$500K ﹤0.01% 1017
2023
Q2
Sell
-42,636
Closed -$1.53M 1335
2023
Q1
$1.53M Sell
42,636
-15,274
-26% -$550K 0.01% 616
2022
Q4
$2.58M Sell
57,910
-22,740
-28% -$1.01M 0.01% 483
2022
Q3
$2.27M Buy
+80,650
New +$2.27M 0.01% 472
2021
Q4
Sell
-12,117
Closed -$654K 1093
2021
Q3
$654K Sell
12,117
-2,416
-17% -$130K ﹤0.01% 719
2021
Q2
$486K Buy
+14,533
New +$486K ﹤0.01% 795
2021
Q1
Sell
-37,346
Closed -$654K 994
2020
Q4
$654K Sell
37,346
-14,233
-28% -$249K ﹤0.01% 690
2020
Q3
$765K Buy
+51,579
New +$765K 0.01% 672
2018
Q4
Sell
-51,337
Closed -$347K 950
2018
Q3
$347K Sell
51,337
-8,675
-14% -$58.6K ﹤0.01% 764
2018
Q2
$453K Buy
60,012
+13,009
+28% +$98.2K ﹤0.01% 792
2018
Q1
$1.64M Buy
47,003
+11,274
+32% +$394K 0.01% 412
2017
Q4
$1.52M Sell
35,729
-79
-0.2% -$3.37K 0.01% 465
2017
Q3
$1.54M Buy
35,808
+1,225
+4% +$52.5K 0.01% 462
2017
Q2
$1.28M Buy
34,583
+29,010
+521% +$1.07M 0.01% 460
2017
Q1
$302K Buy
+5,573
New +$302K ﹤0.01% 729
2015
Q2
Sell
-1,380
Closed -$577K 621
2015
Q1
$577K Sell
1,380
-293
-18% -$123K ﹤0.01% 376
2014
Q4
$458K Buy
+1,673
New +$458K ﹤0.01% 400
2014
Q2
Sell
-7,840
Closed -$2.29M 542
2014
Q1
$2.29M Buy
7,840
+1,653
+27% +$484K 0.02% 260
2013
Q4
$2.39M Sell
6,187
-73
-1% -$28.2K 0.02% 238
2013
Q3
$3.42M Buy
6,260
+2,053
+49% +$1.12M 0.03% 143
2013
Q2
$1.04M Buy
+4,207
New +$1.04M 0.01% 259